Vanda Pharmaceuticals has been granted a patent for using a melatonin agonist to treat circadian rhythm disorders, including in blind patients. The method involves administering tasimelteon to agonize specific receptors in the patient. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of circadian rhythm disorder using tasimelteon
A recently granted patent (Publication Number: US11918557B2) discloses a method for treating patients with circadian rhythm disorders by internally administering tasimelteon to agonize MT1R and MT2R receptors. The method is particularly beneficial for patients who are light perception impaired (LPI) or totally blind, as well as those suffering from Non-24-Hour Sleep-Wake Disorder. Tasimelteon is effective in entraining the patient's cortisol and melatonin circadian rhythms to a 24-hour cycle, promoting a healthy sleep-wake pattern.
The method involves administering tasimelteon in an effective amount ranging from 10 mg to 100 mg per day, with the optimal dosage falling between 20 mg and 50 mg per day. By entraining the patient's circadian rhythms, tasimelteon helps establish a 24-hour sleep-wake cycle, ensuring the patient awakens at or near a target wake time following a daily sleep period of 7 to 9 hours. This patent highlights the potential of tasimelteon in effectively managing circadian rhythm disorders and improving the overall quality of life for affected individuals.
To know more about GlobalData’s detailed insights on Vanda Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
